Detects equine IFN‑ gamma in ELISAs and Western blots. In sandwich immunoassays, approximately 20% cross‑reactivity with recombinant canine IFN‑ gamma is observed, less than 6% cross‑reactivity with recombinant bovine IFN‑ gamma and recombinant feline IFN‑ gamma is observed, and less than 0.2% cross‑reactivity with recombinant human IFN‑ gamma, recombinant mouse IFN‑ gamma, recombinant rat IFN‑ gamma, recombinant porcine IFN‑ gamma, recombinant rhesus macaque IFN‑ gamma, and recombinant cotton rat IFN‑ gamma is observed.
Polyclonal Goat IgG
E. coli-derived recombinant equine IFN-gamma Ala25-Gln166 Accession # P42160
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Recombinant Equine IFN-gamma Protein (Catalog # 1586-HG)
Measured by its ability to neutralize IFN‑ gamma inhibition of EMCV-induced cytopathy in the L‑929 mouse fibroblast cell line. Vogel, S. and M. Hogan (1995) in Current Protocols in Immunology. Ciocio, R. (ed); John Wiley & Sons, Inc. p. 6. 9. 1. The Neutralization Dose (ND50) is typically 0.25-1.25 µg/mL in the presence of 20 ng/mL Recombinant Equine IFN‑ gamma.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
IFN‑ gamma Inhibition of EMCV-induced Cytopathy and Neutralization by Equine IFN‑ gamma Antibody. Recombinant Equine IFN‑ gamma (Catalog # 1586‑HG) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the L‑929 mouse fibroblast cell line in a dose‑dependent manner (orange line), as measured by Resazurin (Catalog # AR002). Inhibition of EMCV activity elicited by Recombinant Equine IFN‑ gamma (20 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Equine IFN‑ gamma Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1586). The ND50 is typically 0.25-1.25 µg/mL.
IFN‑ gamma in Equine PBMCs. IFN‑ gamma was detected in immersion fixed equine peripheral blood mononuclear cells (PBMCs) treated with Calcium Ionomycin and PMA using Goat Anti-Equine IFN‑ gamma Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1586) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
Preparation and Storage
Reconstitute at 0.2 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Interferon-gamma (IFN-gamma ), also known as type II or immune interferon, exerts a wide range of immunoregulatory activities and is considered to be the prototype proinflammatory cytokine (1, 2). Mature equine IFN-gamma exists as a noncovalently linked homodimer of 20‑25 kDa variably glycosylated subunits (3, 4). It shares 73%‑82% amino acid sequence identity with bovine, canine, feline, and porcine IFN-gamma and 42%‑64% with cotton rat, human, mouse, rat, and rhesus IFN-gamma. IFN-gamma dimers bind to IFN-gamma RI (alpha subunits) which then interact with IFN-gamma RII (beta subunits) to form the functional receptor complex of two alpha and two beta subunits. Inclusion of IFN-gamma RII increases the binding affinity for ligand and the efficiency of signal transduction (5, 6). IFN-gamma is produced by a variety of immune cells under inflammatory conditions, notably by T cells and NK cells (7). It plays a key role in host defense by promoting the development and activation of Th1 cells, chemoattraction and activation of monocytes and macrophages, upregulation of antigen presentation molecules, and immunoglobulin class switching in B cells. It also exhibits antiviral, antiproliferative, and apoptotic effects (7, 8). In addition, IFN-gamma functions as an anti-inflammatory mediator by promoting the development of regulatory T cells and inhibiting Th17 cell differentiation (9, 10). The pleiotropic effects of IFN-gamma contribute to the development of multiple aspects of atherosclerosis (8).
Billiau, A. and P. Matthys (2009) Cytokine Growth Factor Rev. 20:97.
Pestka, S. et al. (2004) Immunol. Rev. 202:8.
Grunig, G. et al. (1994) Immunogenetics 39:448.
Curran, J.A. et al. (1994) DNA Seq. 4:405.
Marsters, S.A. et al. (1995) Proc. Natl. Acad. Sci. 92:5401.
Krause, C.D. et al. (2000) J. Biol. Chem. 275:22995.
Schroder, K. et al. (2004) J. Leukoc. Biol. 75:163.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.